148 related articles for article (PubMed ID: 38622869)
1. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
[TBL] [Abstract][Full Text] [Related]
2. Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa - KINDLE Study.
Jazieh AR; Sağlam EK; Önal HC; Abdelkader Y; Gaafar R; Dawoud E; Nassar M; Alshorbagy D; El Ashry H; Elsayed M
Clin Lung Cancer; 2022 Jun; 23(4):364-373. PubMed ID: 35277345
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort.
Aboelhassan R; Sobeih ME; El-Din MA; Ghali RR; El-Din IS; Khorshid O; Mokhtar M; Rabea AM; Belal A; Azim HA; Abdullah M; Elnahas T; Tawfik H; Abdelwahab S; Elsaid AA; Hashem T; Mancy M; Farag H
Ther Adv Med Oncol; 2023; 15():17588359231212182. PubMed ID: 38028146
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study.
Jazieh AR; Onal HC; Tan DSW; Soo RA; Prabhash K; Kumar A; Huggenberger R; Robb S; Cho BC
J Thorac Oncol; 2021 Oct; 16(10):1733-1744. PubMed ID: 34051381
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III Non-Small-Cell Lung Cancer: Results of KINDLE-Vietnam Cohort.
Van Dao T; Diep TB; Le Phuong T; Huggenberger R; Kumar A
Front Oncol; 2022; 12():842296. PubMed ID: 35677172
[TBL] [Abstract][Full Text] [Related]
6. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2020 Aug; 146():112-119. PubMed ID: 32526601
[TBL] [Abstract][Full Text] [Related]
7. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H; Atagi S; Oizumi S; Ohashi K; Kato T; Kozuki T; Seike M; Sone T; Sobue T; Tokito T; Harada H; Maeda T; Mio T; Shirosaka I; Hattori K; Shin E; Murakami H
Cancer Med; 2020 Sep; 9(18):6597-6608. PubMed ID: 32730697
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
[TBL] [Abstract][Full Text] [Related]
10. Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset.
Prabhash K; Tan DSW; Soo RA; Sitthideatphaiboon P; Chen YM; Voon PJ; Syahruddin E; Chu S; Huggenberger R; Cho BC
Front Oncol; 2023; 13():1117348. PubMed ID: 37051534
[TBL] [Abstract][Full Text] [Related]
11. Real-world KINDLE-Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non-small-cell lung cancer.
Martin CM; Puello-Guerrero A; Mas-Lopez LA; Campos-Gómez S; Orlando-Orlandi FJ; Tejado Gallegos LF; Huggenberger R
Cancer Med; 2023 Jan; 12(2):1247-1259. PubMed ID: 35789068
[TBL] [Abstract][Full Text] [Related]
12. An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study.
Su PL; Chang GC; Hsiao SH; Hsia TC; Lin MC; Lin MH; Shih JY; Yang CT; Yang SH; Chen YM
JTO Clin Res Rep; 2022 Mar; 3(3):100292. PubMed ID: 35252898
[TBL] [Abstract][Full Text] [Related]
13. Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients: A Real-world Evidence Study.
Yusuf D; Walton RN; Hurry M; Farrer C; Bebb DG; Cheung WY
Am J Clin Oncol; 2020 Sep; 43(9):615-620. PubMed ID: 32889830
[TBL] [Abstract][Full Text] [Related]
14. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V
Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
Peled N; Roisman LC; Levison E; Dudnik J; Chernomordikov E; Heching N; Dudnik E; Keren-Rosenberg S; Nechushtan H; Salhab A; Hershkovitz D; Tsuriel S; Hannes V; Rotem O; Lazarev I; Lichtenberg R; Granot IS; Krayim B; Shalata W; Levin D; Krutman Y; Allen AM; Blumenfeld P; Lavrenkov K; Kian W
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):105-114. PubMed ID: 36925073
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
[TBL] [Abstract][Full Text] [Related]
18. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
Thibodeau S; Meem M; Hopman W; Sandhu S; Zalay O; Fung AS; Kartolo A; Digby GC; Al-Ghamdi S; Robinson A; Ashworth A; Owen T; Mahmud A; Tam K; Olding T; de Moraes FY
Cancer Treat Res Commun; 2023; 36():100747. PubMed ID: 37531737
[TBL] [Abstract][Full Text] [Related]
20. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]